Clovis Oncology Announces Second Quarter 2022 Operating Results and Provides Update on Clinical Development Programs
First presentation of initial LuMIERE Phase 1 clinical data for FAP-2286 targeted radiotherapy candidate at SNMMI demonstrated a manageable safety profile with preliminary evidence of... | August 8, 2022
United States Comunidad Autonoma De Cataluna Patrickj Mahaffy Clovis Oncology Inc European Network Of Gynaecological Oncological Trial Drug Administration
Source: marketscreener.com